Evaluation of selected serum biomarkers levels in response to infliximab reference product (Remicade®) versus it's biosimilar (Remsima®) in a sample of ulcerative colitis patients: a cross-sectional study

Yahya Al-Qaisy

doi:10.5281/zenodo.8164655

Published July 19, 2023 | Version v1

Dataset Open

Evaluation of selected serum biomarkers levels in response to infliximab reference product (Remicade®) versus it's biosimilar (Remsima®) in a sample of ulcerative colitis patients: a cross-sectional study

Yahya Al-Qaisy¹

1. College of Pharmacy - Mustansiriyah University

Evaluation of selected serum biomarkers levels in response to infliximab reference product (Remicade^®) versus it's biosimilar (Remsima^®) in a sample of ulcerative colitis patients: a cross-sectional study

Files

Files (17.0 kB)

Name	Size
Article data.xlsx md5:2d636b0594613bbb20aedb2292f607ac	17.0 kB	Download

114

Views

Downloads

Show more details

	All versions	This version
Views	114	114
Downloads	32	32
Data volume	560.2 kB	560.2 kB

More info on how stats are collected....

DOI

Resource type

Dataset

Publisher

Zenodo

License: Creative Commons Attribution 4.0 International

The Creative Commons Attribution license allows re-distribution and re-use of a licensed work on the condition that the creator is appropriately credited. Read more

Technical metadata

Created: July 19, 2023
Modified: July 20, 2023

Evaluation of selected serum biomarkers levels in response to infliximab reference product (Remicade®) versus it's biosimilar (Remsima®) in a sample of ulcerative colitis patients: a cross-sectional study

Authors/Creators

Description

Files

Files (17.0 kB)